The study was taken to assess the feasibility of diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) mapping using different b-values for magnetic resonance-guided focused ultrasound (MRgFUS) treatment of uterine fibroid and adenomyoma.
Introduction
Uterine fibroids and adenomyoma are benign pathological diseases that have affected women in the reproductive age group. These diseases have caused significant disability and morbidity in patients and constitute a major source of public healthcare cost worldwide (1, 2) . Numerous therapeutic strategies such as hormone therapy, drug therapy, surgical intervention, uterine artery embolization and magnetic resonance-guided focused ultrasound (MRgFUS) ablation, are available to treat uterine fibroids and adenomyoma (2) (3) (4) (5) (6) . The MRgFUS is proven to be a feasible, safe, efficacious treatment for uterine fibroids and adenomyoma (7) (8) (9) (10) (11) (12) (13) (14) by inducing coagulative necrosis, size reduction and functional loss of the lesion (7, 15) . The treatment outcome of MRgFUS ablation is normally assessed by contrast-enhanced T1-weighted image (cT1WI) with the use of gadolinium-based magnetic resonance contrast agent.
Although cT1WI has been widely accepted as the gold standard for treatment outcome evaluation, several limitations are found with the technique. The application of contrast enhanced magnetic resonance imaging (MRI) could be limited due to patient allergies towards gadolinium. Further, overestimation of ablated volume may occur when there is a transient reduction of vascularity in non-treated fibroid tissue due to vessel spasm or other factors (16) . Besides, the unknown hazardous potential and side effects of heating the contrast agent has limited the peri-procedural contrast enhanced imaging. Due to the same reason, additional treatment would need to be scheduled in the cases of incomplete ablation as MRgFUS is not recommended to be applied immediately after the contrast enhanced MRI scan. In view of the above, the method which could be used for peri-and post-procedural treatment outcome evaluation is therefore favourable.
The diffusion-weighted imaging (DWI) may be feasible to serve as a "functional parameter" to evaluate the periand post-procedural treatment outcome by displaying the contrast based on the differences in the water molecules diffusivity within intra-and extracellular spaces. Various studies have reported the use of DWI and apparent diffusion coefficient (ADC) mapping in monitoring and assessing the treatment outcomes of MRgFUS of the uterine fibroids and uterine artery embolization (17) (18) (19) (20) (21) (22) (23) . However, the correlation between the quantitative volume measurements of the ablated fibroid or adenomyoma obtained from DWI or ADC map and post-contrast nonperfused volume (NPV) obtained from standard cT1WI are not known to be performed previously.
Hence, this study was taken to assess the feasibility of DWI and ADC map in quantitative treatment volume measurement, immediately after MRgFUS treatment and at 12 months follow-up. In particular, our aim was to investigate which image (DWI or ADC map) and which b-value (200, 600 or 800 s/mm 2 ) would provide a better correlation to the standard cT1WI non-perfused volume results.
Methods

Patient population
Patients who have been diagnosed with uterine fibroid or adenomyoma were recruited in this study. The inclusion and exclusion criteria are as follows:
Inclusion Criteria:
• Premenopausal women older than 18 years or peri-menopausal women with a normal cervical smear and symptomatic fibroid or adenomyosis disease.
• Patients with confirmed fibroid disease or adenomyoma by clinical examination and deemed suitable for treatment by MR imaging.
Exclusion Criteria:
• Menstruating, pregnant or lactating women.
• Patients having contraindication to standard MR imaging, IV sedation or IV gadolinium chelate.
• Patients with suspected or confirmed uterine malignancy, other pelvic diseases or major systemic diseases.
• ). The ADC maps were constructed from the DWI data using the dedicated software. Following DWI, the contrast-enhanced imaging was performed using axial 3D gradient echo T1WI sequence after administration of 10 ml intravenous bolus of Gadopentetate Dimeglumine (Magnevist; Bayer HealthCare Pharmaceuticals Inc., Berlin, Germany).
Both pre-and post-contrast enhanced T1WI were used to determine the lesion's viability while T2WI was used to measure and calculate the volume of the treatable fibroid or adenomyoma by assuming the volume (v) of a prolate ellipsoid using the following equation:
where L, W and AP represent the length, width and anteroposterior length of the lesion in cm, respectively. The DWIs and ADC maps were used for quantitative volume assessment of the NPV.
Magnetic resonance-guided focused ultrasound treatment
The MRgFUS treatment of all patients was performed in the prone position using the MRgFUS system (ExAblate® 2000, InSightec, Israel) following the standard procedure as described earlier (24). Patients were under conscious sedation and given optimized pain relief with the vital signs such as blood pressure and pulse rate being monitored throughout the procedure. The occurrence of any adverse events such as skin burns, bowel injury and sciatica was recorded during or immediately after the procedure. The patients were discharged after a minimum of 2 hours' observation or until the effects of conscious sedation wore off.
Patient follow-up
Patients were followed up at 12 months after MRgFUS procedure by a repeated routine pelvic MRI following the same imaging protocol as mentioned above.
Image analysis
The image contrast between the ablated and non-ablated regions on cT1WIs, DWIs and ADC maps, both immediately after the treatment and at 12 months follow-up, were evaluated by two senior radiologists using the scoring system below: The NPVs were assessed from the cT1WIs, DWIs and ADC maps by two independent senior radiologists using the inherent volume calculation software in the MRI workstation (Signa HDxt 1.5T, General Electric Healthcare, USA). The radiologists independently and manually contoured the non-enhanced / devascularized regions by summation of sequential axial slices on the different MR images to calculate the NPV. All evaluation and measurement were performed under a blinded condition to avoid bias. The NPV ratios of the fibroid and adenomyoma were calculated by dividing the NPV with the lesion volume measured on the T2WI before the treatment.
Statistical analysis
The reproducibility of the image contrast scores and NPV values obtained from two independent radiologists were examined using interclass correlation coefficient 
Results
Patient characteristics
Nine fibroid and five adenomyoma patients (39 ± 8 years old), with no concurrent medical disease or previous surgery, have participated in the study and all patients underwent MRgFUS treatment successfully. No adverse reaction was reported except that one patient experienced a mild degree of superficial abdominal skin burn immediately after treatment. Following MRgFUS treatment, eleven patients managed to be followed up after 12 months while two fibroid patients were lost in the follow-up and one adenomyoma patient had undergone a hysterectomy due to persistent menorrhagia. The flow of patients' recruitment in the study is presented in Figure 1 . 
Lesion characteristics
Signal intensity changes were not noted in any of the cT1WIs, DWIs and ADC maps acquired before the treatment, indicating no necrosis or degeneration within the lesion. Immediately after the treatment, the ablated regions on DWIs demonstrated hyperintense signals, showing a good visual agreement with the hypointense non-perfused regions on the cT1WIs. The signal intensity changes on ADC maps (mainly hypointense signals) appeared to be inconsistent and varied between different patients where some lesions showed a mixed and heterogeneous signal intensity change. At 12 months follow-up, despite some changes in size and appearance, the non-perfused regions were found persistent on the cT1WIs of all patients. The signal intensity of the ablated regions on DWIs and ADC maps appeared to be heterogeneous in some cases (mainly on ADC maps). Figures 2 and 3 showed the examples of MR images acquired during pre-treatment, immediately after treatment and at 12 months follow-up, for fibroid and adenomyoma patients, respectively. 2 compared to other DWIs and all ADC maps. (C) At 12 months follow-up: Nonperfused area on cT1WI persisted. Non-perfused area was appreciated on the DWIs. A poor delineation of nonperfused area and poor contrast between ablated and non-ablated regions were observed on ADC maps due to low signal to noise ratio Image contrast score A good inter-observer agreement (ICC = 0.992) were observed between the image contrast scores obtained from two independent radiologists and therefore an average reading was used in subsequent analysis. The image contrast scores of cT1WIs, DWIs and ADC maps of patients can be visualized from Figure 4 and the scores are listed in Supplementary Table 1 . The cT1WI has demonstrated the best contrast between the ablated and non-ablated regions, and therefore was given a full score of 5.
The contrast scores of DWIs and ADC maps of different b-values obtained immediately after the treatment were significantly lower (p < 0.05) than the contrast score of cT1WIs ( Figure 4A and Table 1 (Table 3) .
The linear regression analysis was performed on the NPVs obtained from DWIs, ADC maps and CT1WIs, both immediately after the treatment ( Figure 5A-C) , and at 12 months follow-up ( Figure 5D-F 
Therapeutic outcome analysis
The NPV ratio served as a reflection of the ablation percentage where the ablation percentage is equal to NPV ratio of 100%. The NPV ratios were calculated for all treated lesions immediately after the treatment and at 12 months follow-up (Table 4 ). The statistical analysis results of NPV ratio obtained from cT1WI, DWIs and ADC maps are given in Table 5 . Immediately after the treatment, only the NPV ratio derived from DWI of 200 s/mm² was essentially similar to the post-contrast NPV ratio (p = 0.075), while the NPV ratios of other DWIs and all ADC maps were statistically different from the post-contrast NPV ratio (p < 0.05). The NPV ratios obtained from DWIs were also different from the NPV ratios obtained from ADC maps at p < 0.05 (Table 5) .
At 12 months follow-up, the NPV ratio derived from cT1WI was found similar to the NPV ratios obtained from all DWIs and ADC maps of different b-values (p > 0.05). It should be noted from the Table 5 , only the differences between the NPV ratios of DWI and ADC map of 200 s/mm² were considered significant, while the NPV ratios of DWIs and ADC maps of 600 s/mm² and 800 s/mm² were similar to each other. On the other hand, the ablated regions on the DWIs and ADC maps were formed due to, either the perfusion effect from vessel destruction during the treatment, or cytotoxic oedema. The DWI and ADC maps can be used to evaluate the peri-and post-procedural treatment outcome for MRgFUS treatment of uterine fibroid and adenomyoma. The peri-procedural monitoring using DWI and ADC maps could provide more information and feedback to the physician on the treatment planning and tumour ablation. For the post-procedural treatment outcome evaluation, the non-perfused region can be delineated from both the DWI and ADC maps for the determination of NPV and NPV ratio.
The DWI of 200 s/mm² has demonstrated the best image contrast and displayed the clearest visualization of the ablation border compared to other DWIs and ADC maps immediately after the treatment. This observation was in agreement with previously published data, suggesting the lower b-value would have produced a better image contrast (17, 23) . The poorer image contrast of DWIs obtained with b-values of 600 s/mm² and 800 s/mm² can be ascribed to low signal-to-noise ratio due to shorter T2 relaxation times (25). Immediately after the treatment, the appearance of the treated regions on all the ADC maps appeared to be unpredictable, similar to those observed by Pilatou et al. (22) . The treated regions on ADC maps showed significant areas of heterogeneity which perhaps reflected the differences in the tissue cellularity and properties. The poor contrast resolution of ADC maps obtained at lower b-values was also noticed as the result of low signal attenuation. However, a slight improvement in image resolution was appreciated in the ADC map of 800 s/mm² as a higher signal attenuation was achieved at the higher b-value.
At 12 months follow-up, the image contrast of both DWIs and ADC maps of different b-values were generally poor due to heterogeneity of the ablated region and hence yielded a lower image contrast score. Since no significant difference was noticed between the contrast scores of DWIs and ADC maps of different b-values, there was no specified b-value to be considered as superior in delineating the ablated region at 12 months follow-up. Our results appear to contradict earlier reports (17, 23) that suggested that better ADC map contrast was produced with higher b-values (400, 600 and 800 s/mm²) during 1 month follow-up due to the diffusion effects. Such differences noted can be ascribed to the different length of the follow-up period (1 month in the earlier reports against 12 months in our study). In view of this, a further investigation on a larger scale should be performed to determine the influence of different b-values on image contrast at different follow-up periods.
The NPVs as measured from the DWIs and ADC maps showed an under-estimated ablation volume in most of the patients when compared to the post-contrast NPV, both immediately after and 12 months after the treatment. The NPV derived from DWIs showed a better correlation to the post-contrast NPV compared to those obtained from ADC 
Discussion
The cT1WI is the gold standard for the assessment of a region or volume after MRgFUS treatment. Due to the relatively lower contrast uptake by the ablated region, it appeared as a hypointense region on cT1WI, and is known as a non-perfused region. The volume of the non-perfused region has been widely used for treatment effectiveness maps with the best correlation demonstrated by the DWI of 200 s/mm². The higher image contrast of the DWI obtained with b-value of 200 s/mm² has allowed a better delineation and a higher measurement accuracy of the ablated region. This finding was in agreement with the results reported earlier (17, 23) , hence suggesting a better depiction of the ablated region on the lower b-value images. Furthermore, it has been suggested that the visual comparison of the DWIs of higher b-values to the contrast-enhanced MR images are less precise (17, 23) . The NPVs derived from all ADC maps have demonstrated a poor correlation with the post-contrast NPV, which can be attributable to the poorer image contrast of the ADC maps. The low signal-to-noise ratio and signal heterogeneity seemed to be responsible for the poorer image contrast of ADC maps.
At 12 month follow-up, a notable decrease in the NPVs was observed on all the patients accessed. Both the DWIs and the ADC maps showed an inconsistent and more heterogeneous signal changes at 12 months follow-up. There were four patients who showed no measurable NPVs on the DWIs and ADC maps. Out of these four patients, two of them had also no measurable post-contrast NPV.
The patients who demonstrated no discernible DWI or ADC map signal changes at follow-up were the adenomyoma patients where three of the adenomyoma patients did not show any signal changes on both DWIs and ADC maps while the remaining patient, who although demonstrated DWI signal changes, did not show apparent ADC map signal changes. The main reason for the above observation was not fully understood but it may be due to the nature of the lesion where the tissue recovery rate and response to the MRgFUS procedure might vary. Anyhow, these observations indicated the limitation of using DWI or ADC map to assess the treatment outcome of MRgFUS during followup periods. Except for those cases mentioned above, the delineation of the NPV was still possible in the remaining cases at 12 months follow-up. There was a good correlation with no significant difference between the post-contrast NPV and volumes derived from all the DWIs and ADC maps of different b-values at follow-up.
The NPV ratio calculated from cT1WI, DWIs and ADC maps reflected the percentage of ablation. Immediately after the treatment, the NPV ratios calculated from the DWI of 200 s/mm² correlated well with the post-contrast NPV ratio, suggesting the DWI with a lower b-value could be employed as a measurement parameter to assess the MRgFUS treatment outcome. At 12 months follow-up, the NPV ratios calculated from DWIs and ADC maps of different b-values correlated well with the post-contrast NPV ratio. The smaller lesion size, and hence, lower NPV ratio at follow-up has allowed a lesser error in ablated region delineation and this may be responsible for the above observation.
There are several advantages for the application of DWI and ADC maps for MRgFUS treatment outcome evaluation. Despite being used for post-procedural outcome evaluation, the DWI and ADC maps can be used for peri-procedural monitoring as no contrast agent is involved. In addition, the ablation can be performed immediately after the post-procedural MR scanning for the patient with incomplete tumour ablation, as hazardous potential of heating the contrast agent is not involved for DWI and ADC maps. The DWI and ADC maps also enabled the non-invasive evaluation of multiple ablated lesions simultaneously and provided a faster imaging time. In addition, the DWI and ADC maps obviate the contrast agent injection which decreases the possible chance of systemic reaction to the contrast agent. As the method does not involve the use of contrast agent, the treatment cost may be further reduced (18) . Nonetheless, the DWI and ADC maps are limited by the motion artefacts. Although use of echo-planar MR imaging for a patient lying in a prone position with conscious sedation may reduce the motion artefacts, it may be a major limitation, however, for the use of DWI and ADC maps. Furthermore, some patients may show a poorer contrast in the DWI and ADC maps which may lead to inaccurate delineation of the non-perfused area and thus the NPV calculation. Hence, selection of the b-value that gives a better contrast of DWI and ADC maps is crucial.
A major limitation of this study was the small sample size as a limited number of patients fulfilled the inclusion criteria, and some patients were lost during follow-up. Since this was a preliminary study involving the use of multiple b-values for DWI and ADC maps, a larger sample size study, preferably, a randomized controlled trial from multi-centres, is needed to assess the efficacy of DWIs and ADC maps of different b-values to evaluate the treatment outcome of MRgFUS of uterine fibroids and adenomyoma.
Conclusion
In conclusion, this study demonstrated the feasibility and effectiveness of treated uterine fibroid or adenomyoma volume measurements after MRgFUS treatment using DWIs and ADC maps of different b-values. The DWI obtained with a low b-value (200 s/mm²) is a feasible alternative for delineation and quantitative volumetric evaluation of ablated region immediately after the treatment. Despite some degree of under-estimation, the ablated volume measured from the DWI of 200 s/mm² was comparable to the volume obtained from cT1WI. Furthermore, our study also demonstrated a good image contrast and showed a good correlation with the post-contrast NPV ratio. The DWI obtained with a higher b-value (600 and 800 s/mm²) was found less accurate for volume measurement while all the ADC maps of different b-value showed a poor image contrast and significant NPV under-estimation. 
